Soros Fund Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Soros Fund Management’s Portfolio ONCE Stock Details ONCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-7,500	Closed	-$581K	–	304
2015 Q1	$581K	Buy	+7,500	New	+$432K	0.01%	214

Other funds holding ONCE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCPEM

Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return

Soros Fund Management's ONCE Position: Q2 2015 in Review

Soros Fund Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q2 2015, closing a stake of 7,500 shares — an estimated $581K sold.

Soros Fund Management first reported a position in ONCE in Q1 2015 and held it in 1 quarter. The position peaked at $581K in Q1 2015. 109 funds tracked by Wall St. Rank hold ONCE as of Q2 2015.

Soros Fund Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
Soros Fund Management sold 7,500 Spark Therapeutics, Inc. Common Stock shares in Q2 2015, an estimated $581K.
Soros Fund Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 1 quarter.
Soros Fund Management's Spark Therapeutics, Inc. Common Stock position peaked at $581K in Q1 2015.
109 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q2 2015.

Based on Soros Fund Management's 13F filing for Q2 2015, filed 14 Aug 2015.